Lung Cancer - Non-Small Cell News

Tagrisso Approved for Treatment of Certain Lung Cancers (April 18, 2017)

The U.S. Food and Drug Administration granted regular approval to Tagrisso (osimertinib) for the treatment of patients with metastatic epidermal growth factor receptor (EGFR) T790M mutation-positive non-small cell lung cancer (NSCLC), as detected by an... Continue Reading

Opdivo Appears to Significantly Improve Five-Year Survival Rates in Advanced Lung Cancer (April 13, 2017)

Treatment with the immune checkpoint inhibitor Opdivo (nivolumab) yielded durable responses in some patients with advanced non-small cell lung cancer (NSCLC), with a five-year survival rate of 16 percent, according to data presented here at the AACR Annual... Continue Reading

Zykadia receives FDA Priority Review for first-line use in patients with ALK+ metastatic NSCLC (March 7, 2017)

The US Food and Drug Administration (FDA) granted Priority Review for the expanded use of Zykadia® (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are anaplastic lymphoma kinase (ALK)-positive... Continue Reading

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading

Personalized Lung Cancer Care & Precision Medicine (November 8, 2016)

Targeted and more-individualized treatment for NSCLC becomes a reality. Lung cancers used to be diagnosed solely by a visual microscopic examination of tumor tissue and all patients received the same chemotherapy. Now, doctors are personalizing care by... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (October 19, 2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study... Continue Reading

Latest Lung Cancer - Non-Small Cell News By Stage


Recurrent Lung Cancer - Non-Small Cell

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Whole-Brain Radiotherapy Fails to Benefit Most Patients with Lung Cancer (September 13, 2016)

Whole-brain radiotherapy (WBRT) provides “little additional clinically significant benefit” for patients with non–small cell lung cancer (NSCLC) with brain metastases, according to doctors performing the first large-scale randomized controlled... Continue Reading

First Targeted Therapy Shows Promise in Small Cell Lung Cancer (June 7, 2016)

Small cell lung cancer (SCLC) accounts for approximately 20–25% of all lung cancers. SCLC is an aggressive and fast-growing type of cancer that is very responsive to chemotherapy. However, although initial anticancer responses to chemotherapy may be... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

Screening/Prevention Lung Cancer - Non-Small Cell

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung... Continue Reading

Screening Could Reduce Lung Cancer Mortality (April 24, 2013)

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading

Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)

Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading

Female Lung Cancer Deaths on the Rise in Some Areas (July 3, 2012)

Lung cancer deaths are on the rise among young and middle-aged white women, mainly in the South and the Midwest, according to a study published in the Journal of Clinical Oncology. Lung cancer remains the leading cause of cancer death among both men and... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Stages I-IIIA Lung Cancer - Non-Small Cell

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

Immunotherapy May Become New Standard of Care in Advanced Non-Small Cell Lung Cancer (October 19, 2016)

Researchers presented full results of Keytruda® (pembrolizumab) and Opdivo® (nivolumab) in previously untreated advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology annual meeting in Copenhagen. An additional study... Continue Reading

Opdivo® Receives Expanded Approval for an Additional Type of Lung Cancer (October 19, 2015)

The United States Food and Drug Administration (FDA) has expanded the approval of Opdivo® (nivolumab) for the treatment of non-squamous, non-small cell lung cancer. Non-small cell lung cancer (NSCLC), the most common type of lung cancer, is divided into... Continue Reading

Non-Small Cell Lung Cancer: The ALCHEMIST Lung Cancer Trials (January 14, 2015)

The cancer research community is moving forward in its efforts find more effective treatment for patients with lung cancer. Current clinical trials are taking innovative approaches to how therapies for both advanced and early-stage lung cancers are studied.... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages IIIB-IV Lung Cancer - Non-Small Cell

Many Late Stage Lung Cancer Patients do not Receive Treatment (January 24, 2017)

A national study by researchers at UC Davis Comprehensive Cancer Center has found that a significant number of lung cancer patients are not receiving treatment. Based on data between 1998 and 2012 from the National Cancer Database, 21 percent of patients... Continue Reading

Tagrisso®: New Standard of Care for Certain Lung Cancer (December 19, 2016)

Treatment with the targeted agent Tagrisso (osimertinib) significantly delayed cancer progression, and resulted in fewer side effects, than standard chemotherapy for patients with advanced non-small cell lung cancer (NSCLC) whose cancer had progressed... Continue Reading

Precision Medicine Guides NSCLC Cancer Treatment: All Patients Should Undergo Molecular Testing (October 27, 2016)

Lung cancer remains the leading cause of cancer-related deaths worldwide. In the United States, non-small cell lung cancer (NSCLC) accounts for 75–80% of all lung cancers. Although progress has been made in recent years, the majority of patients with... Continue Reading

Keytruda Approved for First-Line Treatment of Select Patients with Advanced Non-Small Cell Lung Cancer (October 25, 2016)

The US Food and Drug Administration (FDA) has approved Keytruda® (pembrolizumab) as a first-line treatment options for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors express high levels of PD-L1 without EGFR or ALK mutations. PD-1... Continue Reading

Tecentriq® Improves NSCLC Survival Compared to Chemotherapy Regardless of PD-L1 Status (October 25, 2016)

Tecentriq® (atezolizumab) improves the outcomes of individuals with advanced non-small cell lung cancer (NSCLC) according to the results of a pivotal clinical trial presented at the European Society of Medical Oncology (ESMO) 2016 Annual Meeting this... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell